Comment on: Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database.
作者信息
Khouri Charles, Hlavaty Alex, Revol Bruno, Salvo Francesco, Raschi Emanuel
机构信息
Pharmacovigilance Unit, Grenoble Alpes University Hospital, Université Grenoble Alpes, F-38000 Grenoble, France.
HP2, Inserm U1300, Université Grenoble Alpes, Grenoble, France.
出版信息
Ther Adv Neurol Disord. 2024 Sep 12;17:17562864241276847. doi: 10.1177/17562864241276847. eCollection 2024.
Abstract
摘要
相似文献
1
Comment on: Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database.评论：探索减肥药物与多发性硬化症之间的关联：来自美国食品药品监督管理局不良事件报告系统数据库的见解。
Ther Adv Neurol Disord. 2024 Sep 12;17:17562864241276847. doi: 10.1177/17562864241276847. eCollection 2024.
2
Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database.探索减肥药物与多发性硬化症之间的关联：来自美国食品药品监督管理局不良事件报告系统数据库的见解
Ther Adv Neurol Disord. 2024 Apr 1;17:17562864241241383. doi: 10.1177/17562864241241383. eCollection 2024.
3
Author response to Comment on: Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database.作者对关于《探索减肥药物与多发性硬化症之间的关联：来自美国食品药品监督管理局不良事件报告系统数据库的见解》评论的回复
Ther Adv Neurol Disord. 2024 Sep 17;17:17562864241276848. doi: 10.1177/17562864241276848. eCollection 2024.
4
Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database.基于 FDA 不良事件报告系统数据库的真实世界研究：抗肥胖药物与消化道不良事件关联性的分层分析。
BMC Pharmacol Toxicol. 2024 Sep 12;25(1):64. doi: 10.1186/s40360-024-00789-9.
5
A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.美国食品和药物管理局不良事件报告系统（FAERS）数据库中 2012 年至 2017 年间批准的心血管疾病药物不良药物反应报告的药物警戒研究。
Cardiovasc Drugs Ther. 2022 Apr;36(2):309-322. doi: 10.1007/s10557-021-07157-3. Epub 2021 Feb 18.
6
Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021.药物性间质性肺疾病：一项对2004年至2021年美国食品药品监督管理局不良事件报告系统的真实世界药物警戒研究。
Ther Adv Drug Saf. 2024 Jan 27;15:20420986231224227. doi: 10.1177/20420986231224227. eCollection 2024.
7
Identifying Medications Underlying Communication Atypicalities in Psychotic and Affective Disorders: A Pharmacovigilance Study Within the FDA Adverse Event Reporting System.识别精神分裂症和情感障碍中沟通异常的潜在药物：FDA 不良事件报告系统中的药物警戒研究。
J Speech Lang Hear Res. 2023 Sep 13;66(9):3242-3259. doi: 10.1044/2023_JSLHR-22-00739. Epub 2023 Jul 31.
8
Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database.药物所致严重皮肤不良反应：一项使用美国食品药品监督管理局不良事件报告系统数据库的真实世界药物警戒研究
Front Pharmacol. 2023 Apr 4;14:1117391. doi: 10.3389/fphar.2023.1117391. eCollection 2023.
9
Weight gain, gender, and antipsychotics: a disproportionality analysis of the FDA Adverse Event Reporting System database (FAERS).体重增加、性别与抗精神病药物：对美国食品药品监督管理局不良事件报告系统数据库（FAERS）的不成比例分析
Expert Opin Drug Saf. 2024 Feb;23(2):239-245. doi: 10.1080/14740338.2023.2248873. Epub 2023 Aug 21.
10
Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database.利妥昔单抗和奥瑞珠单抗的不良事件谱差异：来自 FDA 不良事件报告数据库的研究结果。
Mult Scler. 2021 Jun;27(7):1066-1076. doi: 10.1177/1352458520949986. Epub 2020 Aug 21.
本文引用的文献
1
The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration.《使用药物警戒中的个体病例安全报告进行药物安全性信号检测的不适当性分析报告（READUS-PV）：解释与说明》。
Drug Saf. 2024 Jun;47(6):585-599. doi: 10.1007/s40264-024-01423-7. Epub 2024 May 7.
2
Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database.探索减肥药物与多发性硬化症之间的关联：来自美国食品药品监督管理局不良事件报告系统数据库的见解
Ther Adv Neurol Disord. 2024 Apr 1;17:17562864241241383. doi: 10.1177/17562864241241383. eCollection 2024.
3
Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database.利用美国食品药品监督管理局不良事件报告系统（FAERS）数据库进行药物重新利用。
Curr Drug Targets. 2024;25(7):454-464. doi: 10.2174/0113894501290296240327081624.
4
Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System.肌萎缩侧索硬化症作为一种药物不良反应：食品和药物管理局不良事件报告系统的比例失调分析。
Drug Saf. 2022 Jun;45(6):663-673. doi: 10.1007/s40264-022-01184-1. Epub 2022 May 24.
5
Disproportionality analysis in VigiBase as a drug repositioning method for the discovery of potentially useful drugs in Alzheimer's disease.利用 VigiBase 进行不均衡分析，作为一种药物重定位方法，以发现阿尔茨海默病中具有潜在用途的药物。
Br J Clin Pharmacol. 2021 Jul;87(7):2830-2837. doi: 10.1111/bcp.14690. Epub 2020 Dec 23.
6
Drug repurposing in Raynaud's phenomenon through adverse event signature matching in the World Health Organization pharmacovigilance database.通过世界卫生组织药物警戒数据库中的不良事件特征匹配，对雷诺现象进行药物再利用。
Br J Clin Pharmacol. 2020 Nov;86(11):2217-2222. doi: 10.1111/bcp.14322. Epub 2020 May 14.
7
Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System.多发性硬化症作为一种药物不良反应：来自 FDA 不良事件报告系统的线索。
Expert Opin Drug Saf. 2018 Sep;17(9):869-874. doi: 10.1080/14740338.2018.1506763. Epub 2018 Aug 11.
Zotero 插件